{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:37:45Z","timestamp":1793759865833,"version":"4.6.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is an immunogenic but clinically heterogeneous breast cancer subtype. Stromal tumor-infiltrating lymphocytes (TILs), PD-L1 expression, and tumor mutational burden provide useful but incomplete summaries of the tumor immune microenvironment. Spatial immune biomarkers retain tissue architecture and ask where immune cells are located, which cells they contact, and whether local neighborhoods are inflamed, excluded, suppressive, or organized into tertiary lymphoid structures (TLS). In this critical review, we examine CD8+ T-cell proximity, stromal versus intratumoral localization, suppressive myeloid and regulatory T-cell (Treg)-rich niches, TLS maturity, and spatial checkpoint co-expression in TNBC. We also compare multiplex immunofluorescence, multiplexed ion beam imaging by time-of-flight (MIBI-TOF), imaging mass cytometry, spatial transcriptomics, and hematoxylin-and-eosin (H&amp;amp;E)-based artificial intelligence in terms of spatial resolution, molecular depth, formalin-fixed, paraffin-embedded (FFPE) compatibility, scalability, reproducibility, and clinical feasibility. Most reported associations with prognosis or treatment response remain retrospective or exploratory, and their definitions are sensitive to sampling, segmentation, and threshold selection. The most clinically interpretable candidates are compartment-aware TIL measures, CD8+ T-cell-tumor proximity, and TLS-related features, but none is ready to guide treatment independently. Progress will require locked biomarker definitions, multisite analytical validation, external cohorts, and prospective trials with pre-specified spatial endpoints.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1899098","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:28:55Z","timestamp":1788269335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Spatial immune biomarkers in triple-negative breast cancer: emerging evidence, technology trade-offs, and barriers to clinical translation"],"prefix":"10.3389","volume":"17","author":[{"given":"Liuhai","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The Affiliated Xiangshan Hospital of Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The Affiliated Xiangshan Hospital of Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihang","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The Affiliated Xiangshan Hospital of Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The Affiliated Xiangshan Hospital of Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, The Affiliated Xiangshan Hospital of Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/2097920","article-title":"Triple-negative breast cancer: tumor immunogenicity and beyond","volume":"2024","author":"Ibrahim","year":"2024","journal-title":"Int J Breast Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"B7","unstructured":"FDA approves atezolizumab for PD-L1-positive unresectable locally advanced or metastatic triple-negative breast cancer\n          \n          \n          \n          2019"},{"key":"B8","unstructured":"Genentech provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer\n          \n          \n          \n          2021"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.cell.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: a report from the International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","article-title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01536","article-title":"Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy","volume":"40","author":"de Jong","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2022.08.005","article-title":"Tumor-infiltrating lymphocytes (TIL), tertiary lymphoid structures (TLS), and expression of PD-1, TIM-3, LAG-3 on TIL in invasive and in situ ductal breast carcinomas and their relationship with prognostic factors","volume":"22","author":"Acar","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor microenvironment and immunotherapy for triple-negative breast cancer","volume":"12","author":"Guo","year":"2024","journal-title":"biomark Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1038\/s41467-023-37806-0","article-title":"Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer","volume":"14","author":"Carter","year":"2023","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4161\/onci.24720","article-title":"Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy","volume":"2","author":"Loi","year":"2013","journal-title":"Oncoimmunology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz395","article-title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","volume":"30","author":"Park","year":"2019","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1876-x","article-title":"The single-cell pathology landscape of breast cancer","volume":"578","author":"Jackson","year":"2020","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-0026-6","article-title":"Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer","volume":"1","author":"Ali","year":"2020","journal-title":"Nat Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"10215","DOI":"10.1038\/s41467-025-64990-y","article-title":"Systematic benchmarking of imaging spatial transcriptomics platforms in FFPE tissues","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41523-025-00728-9","article-title":"Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer","volume":"11","author":"Liang","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13058-025-02132-4","article-title":"Spatial analysis of tumor immune microenvironment of TNBC with different neoadjuvant chemotherapy outcomes using multiplex immunofluorescence","volume":"27","author":"Park","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/path.6165","article-title":"Spatial analyses of immune cell infiltration in cancer: current methods and future directions: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"260","author":"Page","year":"2023","journal-title":"J Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008875","article-title":"Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing","volume":"13","author":"Taube","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012280","article-title":"Society for immunotherapy of cancer: standards for reporting of multiplex immunohistochemistry\/immunofluorescence assays (STORMI)","volume":"13","author":"Sater","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","article-title":"Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer","volume":"39","author":"Zhang","year":"2021","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020396","article-title":"The emerging role of tertiary lymphoid structures in breast cancer: a narrative review","volume":"16","author":"Narvaez","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507371","article-title":"Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features","volume":"15","author":"Boissi\u00e8re-Michot","year":"2024","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12935-021-02242-x","article-title":"Prognostic impact of tertiary lymphoid structures in breast cancer prognosis: a systematic review and meta-analysis","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081999","article-title":"Dissecting tumor-immune microenvironment in breast cancer at a spatial and multiplex resolution","volume":"14","author":"Tzoras","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002197","article-title":"Multi-institutional TSA-amplified multiplexed immunofluorescence reproducibility evaluation (MITRE) study","volume":"9","author":"Taube","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.2869","article-title":"Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry","volume":"11","author":"Giesen","year":"2014","journal-title":"Nat Methods"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-025-02889-8","article-title":"High-resolution imaging mass cytometry to map subcellular structures","volume":"22","author":"Bollhagen","year":"2025","journal-title":"Nat Methods"},{"key":"B49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12929-022-00879-y","article-title":"Spatial multi-omics analyses of the tumor immune microenvironment","volume":"29","author":"Hsieh","year":"2022","journal-title":"J BioMed Sci"},{"key":"B50","unstructured":"Visium glossary of terms\n          \n          \n          \n          2026"},{"key":"B51","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","article-title":"Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112808","article-title":"Spatial transcriptomic analysis of immune checkpoint blockade response in triple negative breast cancers with tertiary lymphoid structures","volume":"28","author":"Mebane","year":"2025","journal-title":"iScience"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-024-02325-3","article-title":"Systematic comparison of sequencing-based spatial transcriptomic methods","volume":"21","author":"You","year":"2024","journal-title":"Nat Methods"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.1416","article-title":"Spatial interactions of CD103+ tissue-resident memory T cells in the tumor periphery are associated with clinical outcomes in triple-negative breast cancer following neoadjuvant chemotherapy","author":"Lee","year":"2026","journal-title":"Cancer Res Treat"},{"key":"B55","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.cell.2026.04.023","article-title":"AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology","volume":"189","author":"Shulman","year":"2026","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","article-title":"Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer","volume":"42","author":"Shiao","year":"2024","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8","article-title":"A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer","volume":"27","author":"Bassez","year":"2021","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B60","unstructured":"ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials\n          \n          \n          \n          2019"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1899098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:28:57Z","timestamp":1788269337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1899098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2026.1899098"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1899098","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1899098"}}